PI Industries

PI Industries (PIIND) exhibits a strong bearish technical setup as of 2026-11-06, with the stock trading at ₹1735.00, near its 252-day range low (+0.9%). The trend is established across daily, weekly, and monthly horizons, confirmed by ADX readings above 24 and price action consistently below all key moving averages and the Supertrend indicator. Momentum remains negative, evidenced by Minus DI significantly outweighing Plus DI on both daily (45.94 vs 13.16) and weekly (37.69 vs 7.81) charts.

Participation spiked during recent declines; an extreme volume anomaly occurred on 2026-11-05 with a volume ratio of 30.11 accompanying a -19.1% drop. This follows a sequence of reversal patterns, including Evening Star and Doji formations in early November, suggesting sustained selling pressure rather than consolidation. The stock has fallen -53.7% over the past year and is currently down -59.9% from its peak, reflecting high volatility (annualized +31.8%) and significant drawdown risk.

Near-term monitoring should focus on the immediate support level at ₹1653.77 (-4.68%) and resistance at ₹1865.73 (+7.54%). A break below ₹1653.77 would extend downside exposure toward ₹1537.53, while a sustained move above ₹1865.73 would be required to challenge the prevailing downtrend structure.

PI Industries reported a sharp deterioration in Q2 FY27 financials, triggering an 18% single-day stock decline and pushing shares to a 52-week low. Consolidated net profit fell 70% year-on-year to ₹122.2 crore, while standalone net profit dropped 57.8% to ₹207.1 crore. Revenue from operations contracted 9% to ₹1,533.5 crore, driven by an 18% YoY decline in agrochemical exports. Brokerage views are divided: Nuvama maintained a 'HOLD' rating with a reduced target of ₹1,682, citing limited downside potential despite weak performance, while Motilal Oswal reiterated a 'BUY' rating based on a $1.25 billion order book and expectations of gradual demand recovery.

PI Industries (PIIND) reported unaudited financial results for the quarter and half-year ended September 30, 2026, on November 6, 2026. The company’s shares hit a 52-week low of ₹1,735 on this date, down from ₹1,770 previously, extending a multi-year downtrend. This price action follows reported revenue declines of 9.1% year-on-year, driven by an 18% contraction in agrochemical exports and margin pressure. Brokerage views are mixed: Nuvama maintained a 'HOLD' rating with a reduced target price of ₹1,682, citing limited downside potential despite weak quarterly performance, while Motilal Oswal reiterated a 'BUY' rating based on a healthy $1.25 billion order book and expectations of gradual demand recovery.

PI Industries Limited reported unaudited financial results for the half-year ended September 30, 2026, following Board approval on November 4, 2026. Consolidated revenue from operations stood at ₹34,041 million with a profit of ₹3,664 million, while standalone figures showed revenue of ₹31,324 million and profit of ₹5,486 million. The company highlighted strong segment performance in Q2FY27, with Health Sciences revenue growing 20% and Biologicals rising over 45%, though Agchem exports declined approximately 18%. A significant operational improvement was the reduction in net working capital by 18 days (from 139 to 121 days), releasing INR 2,981 million in cash. Additionally, the company unveiled Pioxaniliprole on October 29, 2026, recognized as India’s first indigenously discovered insecticide molecule, which has received registration from the Central Insecticides Board and Registration Committee.

PI Industries faces a near-term earnings contraction and deteriorating cash conversion. For Q2 FY2026-27, revenue remained flat at ₹1,702 crore compared to Q1, while expenses rose sequentially to ₹1,582 crore. This compressed profitability: Profit Before Tax fell from ₹320 crore in Q1 to ₹181 crore in Q2, and Net Profit dropped from ₹244 crore to ₹122 crore. On an annual basis, the TTM sales decline of 17% and profit growth decline of 33% highlight significant operational headwinds.

Financial health shows mixed signals. While borrowings increased to ₹342 crore (Mar 2026) and Cash from Operating Activity fell sharply to ₹474 crore, interest costs have decreased to ₹20 crore (TTM). However, working capital efficiency has worsened markedly; the Cash Conversion Cycle expanded to 119 days (Mar 2026) from 42 days a year prior, driven by rising Debtor Days (88 days) and Inventory Days (157 days). Despite these pressures, the balance sheet remains solvent with Equity growing to ₹11,457 crore as of Sep 2026, and DIIs increasing their stake to 31.39%.

PI Industries faces significant near-term headwinds, evidenced by a sharp deterioration in Q2 FY27 financials and a prolonged technical downtrend. The company reported a 70% year-on-year plunge in consolidated net profit to ₹122.2 crore, alongside a 9% revenue decline driven by an 18% contraction in agrochemical exports. Standalone metrics were similarly weak, with net profit falling 57.8% to ₹207.1 crore and revenue from operations dropping 14.2% to ₹1,533.5 crore. These results triggered a severe market reaction, with shares crashing up to 18% to hit a 52-week low, pushing the stock’s year-to-date losses to over 46%. Technical indicators reinforce this caution: the daily Supertrend is bearish, with the 20-day EMA slope at -65.19 and Plus DI (13.16) significantly trailing Minus DI (45.94). The stock is currently trading at ₹1,735, sitting within a maximum drawdown of -59.9%, while annualized volatility remains elevated at +31.8%. Although brokerages cite a healthy $1.25 billion order book as a potential stabilizer, the immediate operational reality reflects margin pressure and export weakness.